Oncotarget

Research Papers:

Fasudil attenuates soluble fms-like tyrosine kinase-1 (sFlt-1)-induced hypertension in pregnant mice through RhoA/ROCK pathway

Ying Gu, Yaling Feng _, Jinjin Yu, Hua Yuan, Yongxiang Yin, Jian Ding, Jun Zhao, Yaohui Xu, Jianjuan Xu and Haisha Che

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:104104-104112. https://doi.org/10.18632/oncotarget.22017

Metrics: PDF 599 views  |   HTML 952 views  |   ?  


Abstract

Ying Gu1, Yaling Feng1, Jinjin Yu2, Hua Yuan1, Yongxiang Yin3, Jian Ding1, Jun Zhao1, Yaohui Xu1, Jianjuan Xu1 and Haisha Che1

1Department of Obstetrics and Gynecology, Wuxi Maternal and Child Health Hospital Affiliated to Nanjing Medical University, Wuxi, Jiangsu 214002, PR China

2Department of Obstetrics and Gynecology, The Affiliated Hospital of Jiangnan University (Wuxi Fourth People’s Hospital), Wuxi, Jiangsu 214062, PR China

3Department of Pathology, The Affiliated Maternity and Child Health Hospital of Nanjing Medical University, Wuxi, Jiangsu 214002, PR China

Correspondence to:

Yaling Feng, email: 15161506909@163.com

Jinjin Yu, email: fengyl523@sina.com

Keywords: preeclampsia; fasudil; endothelial dysfunction; hypertension; RhoA/ROCK

Received: July 22, 2017    Accepted: September 23, 2017    Published: October 24, 2017

ABSTRACT

Preeclampsia (PE) has become the leading cause of maternal and fetal morbidity and mortality in the world, which is characterized by a systemic maternal inflammatory response associated with endothelial dysfunction, hypertension, and proteinuria. The development of PE is still barely predictable and thus challenging to prevent and manage clinically. Fasudil (FSD), the first-generation Rho/ROCK inhibitor, has been studied widely and applied in clinical practice with high safety and efficacy in treating hypertension and other cardiovascular diseases. However, few studies have focused on the effect of fasudil on preeclampsia in vivo and in vitro. Therefore, the aim of this study is to investigate the effects of fasudil on hypoxia/reoxygenation injury in vitro and its role on preeclamptic animal model. Here, we found that RhoA/ROCK pathway was significantly activated in H/R-challenged endothelial cells and in placenta and umbilical vessel of PE mice. And fasudil pre-treatment can protect vascular endothelial cells from H/R-induced apoptosis. In addition, inhibition of RhoA/ROCK pathway with fasudil can reduce the high blood pressure and urine protein levels as well as the concentration of s-Flt in peripheral and umbilical blood in a dose-dependent manner, thus resulting in prevention of the development of PE. Thus, Fasudil attenuates soluble fms-like tyrosine kinase-1 (sFlt-1)-induced hypertension in pregnant mice through RhoA/ROCK pathway, which would become a potential strategy for PE therapy.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 22017